CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility
Key Highlights
- ➤$6.25 million financing includes approximately $4.0 million gross cash proceeds
- ➤Debt reduced $5.25 million to $12.25 million, saving approximately $0.7 million interest
- ➤Maturity extended one year to July 1, 2028
- ➤Interest-only payments extended through March 31, 2028
- ➤Avenue receives 455,465 shares satisfying $2.25 million principal
CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility PR Newswire
* $4.0 million registered direct offering of common stock, led by existing shareholders and management * $2.25 million of Avenue debt satisfied through the issuance of common stock at the same offering price * Total debt reduced by $5.25 million, to $12.25 million, saving approximately $0.7 million in interest over 12 months * Maturity extended one year to July 1, 2028; interest-only period extended 15 months through March 31, 2028 PRINCETON, N.J., Nov. 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO, the "Company"), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced a $6.25 million common stock financing.
Get started
Create a free account to read the full story.
